Cargando…
The PACMAN-AMI trial: a revolution in the treatment of acute coronary syndromes
After an acute coronary syndrome (ACS), the risk of major adverse cardiovascular events (MACE) persists despite the reperfusion of the culprit lesion. The addition of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) to standard lipid-lowering therapies has been demonstrated to effec...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132619/ https://www.ncbi.nlm.nih.gov/pubmed/37125317 http://dx.doi.org/10.1093/eurheartjsupp/suad040 |